Abstract 102P
Background
Irinotecan monotherapy was the standard second-line treatment regimen for metastatic gastric cancer. Previous researches revealed that apatinib combined with chemotherapy is more effective compared with apatinib or chemotherapy alone.The present study was conducted to evaluate the efficacy and safety of apatinib combined with irinotecan versus irinotecan as second-line or above therapy for patients with advanced or metastatic gastric cancer.
Methods
Patients with advanced or metastatic gastric cancer who have failed prior treatment and treated with apatinib combined with irinotecan or irinotecan from November 2017 to April 2020 were analyzed. The primary end point was progression free survival (PFS). Secondary end points included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety.
Results
26 patients received apatinib combined with irinotecan and 29 patients received irinotecan. The ORR in the combination therapy and monotherapy population were 26.9% and 17.2%, respectively. The DCR in the combination group was higher than in monotherapy population (80.8% vs. 55.2%, P=0.043). Median PFS was 4.2 months in the combination group and 3.3 months in the monotherapy group (P=0.020). Median OS was 8.0 months in the combination group and 5.9months in the monotherapy group (P=0.048).Except for ECOG PS 2, PFS and OS were generally consistent across subgroups by sex, age, number of metastatic sites and primary tumor site. The incidence of Grade 3-4 adverse events in combination and monotherapy group was 23.1% and 20.7%, respectively. In combination group, adverse events that were attributed to apatinib were secondary hypertension (in 7 patients, 26.9%), hand-foot syndrome (5, 19.2%) and proteinuria (5, 19.2%). Univariate analysis demonstrated that secondary hypertension was considered to be a potential predictive factor (P = 0.040) for longer OS in combination group.
Conclusions
Apatinib combined with irinotecan significantly improved PFS, OS and DCR compared with irinotecan as second-line or above therapy for patients with advanced or metastatic gastric cancer, with a tolerable safety profile.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Medical Science and Technique Foundation of Henan Province.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
129P - Chemoradiation in carcinoma esophagus with weekly paclitaxel ad carboplatin: A real-world experience from a tertiary care center
Presenter: Nidhi Sharma
Session: Poster viewing 02
130P - Radiation induced lymphopenia (RAILs on time saves nine): In carcinoma esophagus
Presenter: Sheel Mohanty
Session: Poster viewing 02
131TiP - ASCEND: Randomized, double-blinded phase II study of gemcitabine and nab-paclitaxel with CEND-1 or placebo in untreated metastatic pancreatic ductal adenocarcinoma - An Australasian Gastro-Intestinal Trials Group (AGITG) trial ACTRN12621001290886
Presenter: Andrew Dean
Session: Poster viewing 02
134TiP - A phase I/II study of nanoliposomal irinotecan plus S-1 in metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy
Presenter: Hiroshi Imaoka
Session: Poster viewing 02